Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes Discussion
Newly Diagnosed
New type 2 diagnoses
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="HSSS" data-source="post: 2041333" data-attributes="member: 480869"><p>Nor did I . I found this that seems to give a reasonable explanation </p><p></p><p></p><p><span style="font-size: 22px"><strong>IA-2 antibodies</strong></span></p><p>Islet antigen-2 (IA-2), previously known also as ICA-512, is a major target of islet cell autoantibodies. The protein is found in neural tissue and cells of the pancreatic islets, and its gene has been localized to chromosome 2q35. The cDNA encodes a 979 amino acid transmembrane protein which is enzymatically inactive, and a related PTP-like molecule termed IA-2β or phogrin is also a major islet autoantigen whose location and intracellular domain are 74% identical to IA-2. Autoantibodies to IA-2 are present in up to 80% of children and adolescents at diagnosis of type 1 diabetes. Testing for IA-2A complements GADA measurement, since more than 90% of children have antibodies to at least one of these proteins at diabetes onset. IA-2A generally develops later in the process leading to type 1 diabetes and is therefore associated with more rapid progression. These antibodies do not persist as long following diagnosis as GADA, and are less common in patients who are diagnosed with type 1 diabetes over the age of 30 years. They are therefore less useful than GADA for characterising diabetes in longer term or older patients.</p></blockquote><p></p>
[QUOTE="HSSS, post: 2041333, member: 480869"] Nor did I . I found this that seems to give a reasonable explanation [SIZE=6][B]IA-2 antibodies[/B][/SIZE] Islet antigen-2 (IA-2), previously known also as ICA-512, is a major target of islet cell autoantibodies. The protein is found in neural tissue and cells of the pancreatic islets, and its gene has been localized to chromosome 2q35. The cDNA encodes a 979 amino acid transmembrane protein which is enzymatically inactive, and a related PTP-like molecule termed IA-2β or phogrin is also a major islet autoantigen whose location and intracellular domain are 74% identical to IA-2. Autoantibodies to IA-2 are present in up to 80% of children and adolescents at diagnosis of type 1 diabetes. Testing for IA-2A complements GADA measurement, since more than 90% of children have antibodies to at least one of these proteins at diabetes onset. IA-2A generally develops later in the process leading to type 1 diabetes and is therefore associated with more rapid progression. These antibodies do not persist as long following diagnosis as GADA, and are less common in patients who are diagnosed with type 1 diabetes over the age of 30 years. They are therefore less useful than GADA for characterising diabetes in longer term or older patients. [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes Discussion
Newly Diagnosed
New type 2 diagnoses
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…